Corcept Therapeutics | CORT - 销售和管理费用



金融业
股票价格
USD
资产
USD 888.7M
现金及等价物
USD 111.04M
销售成本
USD 4.06M
流动资产
USD 439.68M
流动负债
USD 153.8M
债务
USD 9.64M
EBIT
USD 41.3M
EBITDA
USD -49M
员工
500
EPS每股收益
USD 0.36
股本和储备
USD 705.78M
销售毛利
USD 252.09M
债务利息支出
USD 888.7M
利息收入
USD 4.89M
市值
USD 12.67B
净收入
USD 42.14M
营业费用
USD 214.85M
营业利润
USD 41.3M
普通股股本
USD 107.33M
PE价格收益
188.23
税前利润
USD -44.72M
销售收入
USD 256.15M
销售和管理费用
USD 156.9M
股票
USD 13.19M
贸易债权人
USD 14.91M
应收帐款人
USD 76.92M


销售和管理费用 更改 日
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Alaunos Therapeutics USD 447K 138K 2026-03
ANI Pharmaceuticals USD 91.66M 18.01M 2026-06
Ardelyx USD 102.27M 26.35M 2026-03
Aurora Cannabis CAD 41.4M 781K 2026-03
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Canopy Growth CAD 31.17M 2.27M 2026-03
Corcept Therapeutics USD 156.9M 28.85M 2026-06
Eli Lilly USD 3.43B 496M 2026-06
J&J USD 6.42B 381M 2026-06
Knight Therapeutics CAD 35.45M 4.43M 2025-12
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Merck USD 2.89B 219M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Novartis USD 3.24B 101M 2026-06
Novartis USD 3.14B 296M 2026-03
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 91.81M 7.93M 2026-06
Pfizer USD 3.41B 496M 2026-06
Supernus Pharmaceuticals USD 133.64M 15.41M 2026-06
TG Therapeutics USD 62.32M 10.82M 2026-06